Michael Gnant, MD, on Duration of Anastrozole Treatment: Results of the ABCSG-16 Trial

2017 San Antonio Breast Cancer Symposium
Tweet this page

Michael Gnant, MD, of the Medical University of Vienna, discusses phase III study findings on giving an additional 2 vs an additional 5 years of anastrozole after the first 5 years of adjuvant endocrine therapy (Abstract GS3-01).

Advertisement

Advertisement



Advertisement